A webinar for scientists interested in the use of implantable pumps as an alternative to serial injections when administering compounds to laboratory animals.
The administration of compounds and dosing methodologies are important considerations when planning experiments using laboratory animals. Injections are often used for animal dosing, but repeated injections over prolonged periods may be inadequate for some compounds (i.e. those with short half-lives) and can lead to great variations in serum concentrations. They are also stressful to the animal and inconvenient for the researcher.
Implantable infusion pumps offer a reliable and convenient alternative to injections and other repetitive dosing methods. They allow greater control and accuracy in drug delivery, thus reducing dosing errors, ensuring stable dose levels and minimizing adverse effects. ALZET Osmotic Pumps have been used in preclinical research for nearly four decades to successfully deliver a wide range of experimental agents. iPRECIO programmable pumps have been developed more recently to facilitate highly demanding dosing requirements.
In this exclusive webinar sponsored by DURECT Corporation, Mr. José Gadea describes the features, benefits and applications of implantable pumps. Discussion focuses on clarifying the most common misconceptions circulating within the research community about implantable infusion pumps. This information is intended to help researchers make more informed decisions when choosing the most appropriate dosing method for their study.
Presenters
José Gadea
José Gadea joins UID from DURECT Corporation, a specialty pharmaceutical company located in Cupertino, California, where he held multiple positions with increasing responsibilities. In his most current role, José served as Senior Product Marketing Manager leading the sales and marketing operations for implantable drug delivery devices (ALZET® and iPRECIO®) and other ancillary products for laboratory animal research. José brings over 19 years of sales and marketing experience promoting and selling products to the life science market. Prior to DURECT, José held the position of therapeutic sales specialist at ALZA Pharmaceuticals. He also has over five years of combined academic and biotechnology research experience in the fields of cancer immunology, cell and gene therapy, infectious diseases, and drug delivery. He has authored and co-authored various scientific publications in peer-reviewed journals, which feature some of his preclinical research work. José earned his Bachelor of Science degree with concentration in Medical Microbiology & Immunology at San Jose State University, California.
Sponsor
